Decoy Therapeutics Reports Promising Ebola Activity for Broad-Spectrum Antiviral Candidate July 27, 2026 by Mathieu Maurice Decoy Therapeutics Inc, a biotechnology company focused on developing Designable Multi-Antivirals (D-MAVs), has announced that one of its D-MAV candidates has demonstrated in vitro effectiveness against the wild-type Ebola Zaire …
